114,685 Shares in CureVac (NASDAQ:CVAC) Bought by Two Sigma Investments LP

Two Sigma Investments LP purchased a new position in shares of CureVac (NASDAQ:CVAC) in the 4th quarter, Holdings Channel.com reports. The institutional investor purchased 114,685 shares of the company’s stock, valued at approximately $391,000.

Several other institutional investors have also bought and sold shares of CVAC. Jump Financial LLC bought a new stake in CureVac during the fourth quarter worth $55,000. D. E. Shaw & Co. Inc. bought a new stake in CureVac during the fourth quarter worth $66,000. XTX Topco Ltd grew its holdings in CureVac by 90.2% during the fourth quarter. XTX Topco Ltd now owns 24,365 shares of the company’s stock worth $83,000 after buying an additional 11,553 shares in the last quarter. Barclays PLC grew its holdings in CureVac by 51.8% during the fourth quarter. Barclays PLC now owns 34,836 shares of the company’s stock worth $118,000 after buying an additional 11,890 shares in the last quarter. Finally, Signaturefd LLC grew its holdings in CureVac by 29.2% during the fourth quarter. Signaturefd LLC now owns 36,140 shares of the company’s stock worth $123,000 after buying an additional 8,170 shares in the last quarter. Institutional investors own 17.26% of the company’s stock.

CureVac Stock Down 4.7%

CVAC stock opened at $4.27 on Wednesday. The stock’s fifty day simple moving average is $3.62 and its two-hundred day simple moving average is $3.44. The company has a current ratio of 6.20, a quick ratio of 6.19 and a debt-to-equity ratio of 0.05. CureVac has a 1-year low of $2.37 and a 1-year high of $5.00. The stock has a market cap of $957.92 million, a P/E ratio of 7.76 and a beta of 2.49.

CureVac (NASDAQ:CVAC) last posted its quarterly earnings data on Thursday, May 22nd. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.08). CureVac had a return on equity of 21.98% and a net margin of 20.72%. The business had revenue of $0.94 million during the quarter, compared to analysts’ expectations of $4.27 million. Analysts expect that CureVac will post 0.72 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the company. UBS Group decreased their price target on CureVac from $13.00 to $12.00 and set a “buy” rating for the company in a report on Wednesday, April 30th. JMP Securities reissued a “market outperform” rating and issued a $10.00 price objective on shares of CureVac in a research report on Wednesday, May 28th.

CureVac Company Profile

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.